JupiteX Get the app
Health & Medicine16 Nov 2026 · about 6 min

HIV drug lenacapavir found to disrupt virus formation, creating giant noninfectious particles

The brief

Lenacapavir can make newly forming HIV particles grow to more than 200 nanometers and leave them unable to cause infection. That is a striking additional effect of a drug already known to block key steps in HIV replication after the virus enters a cell. The research team found that lenacapavir binds to Gag, a precursor protein that helps build new particles, as well as to mature capsid protein. Binding to Gag disrupts normal assembly. The result can be virus-like particles much larger than typical HIV particles, which measure around 100–130 nanometers. The abnormal particles can still fuse with and enter target cells, but they cannot establish productive infection. The study therefore indicates that lenacapavir interferes with HIV at more than one stage of its life cycle, including particle formation. The researchers hope this finding will help guide improved capsid-targeting drugs and next-generation HIV treatments.

01

How does lenacapavir disrupt the formation of new HIV particles?

Lenacapavir can make newly forming HIV particles grow to more than 200 nanometers and leave them unable to cause infection. That is a striking additional effect of a drug already known to block key steps in HIV replication after the virus enters a cell.

The research team found that lenacapavir binds to Gag, a precursor protein that helps build new particles, as well as to mature capsid protein. Binding to Gag disrupts normal assembly. The result can be virus-like particles much larger than typical HIV particles, which measure around 100–130 nanometers.

The abnormal particles can still fuse with and enter target cells, but they cannot establish productive infection. The study therefore indicates that lenacapavir interferes with HIV at more than one stage of its life cycle, including particle formation. The researchers hope this finding will help guide improved capsid-targeting drugs and next-generation HIV treatments.

02

How large are the abnormal particles compared with typical HIV particles?

The abnormal virus-like particles formed in the study measure more than 200 nanometers in diameter. Typical HIV particles are generally around 100–130 nanometers across. This means the particles produced under lenacapavir’s effect are considerably larger than the usual particles described by the researchers.

The difference is linked to disrupted assembly, not to a change in the size of an ordinary particle after it has formed. Lenacapavir binds to Gag, a precursor protein involved in building new virus particles. The researchers found that this interaction promotes the formation of unusually large particles during HIV’s late life-cycle stages.

Size alone is not the key measure of whether these particles can spread infection. The article reports that the abnormal particles can fuse with and enter target cells, yet cannot establish productive infection. The findings reveal another way lenacapavir acts against HIV and may inform the development of improved capsid-targeting drugs and next-generation treatments.

03

Why can these abnormal particles enter a cell but still fail to cause a productive infection?

The surprising point is that entering a cell does not guarantee that a virus can successfully infect it. The abnormal particles produced in the presence of lenacapavir can still fuse with and enter target cells, but the researchers found that they cannot establish productive infection.

Lenacapavir disrupts particle formation by binding to Gag, the precursor protein that helps assemble new HIV particles. This promotes unusually large particles. The study reports their failure to cause productive infection, but the source does not explain the precise reason these particles fail after entry. In general, a virus must complete further steps inside a host cell to produce infectious copies; entry alone is not enough.

The result shows that lenacapavir can interfere with HIV during particle formation as well as at other replication steps. The researchers hope the mechanism will guide improved capsid-targeting drugs and next-generation HIV treatments. The finding does not mean the abnormal particles cannot enter cells; it distinguishes cell entry from successful infection.

04

What is Gag, and what role does it play in building new HIV particles?

Gag is a protein precursor that helps HIV build new virus particles. In the study, it matters because lenacapavir was found to bind to Gag during the late stages of the virus’s life cycle, when particles are assembled and released from infected cells.

The researchers found that lenacapavir binds both precursor Gag and mature capsid protein, even though they differ in structure and assembly state. Its interaction with Gag disrupts normal assembly and promotes unusually large virus-like particles, measuring more than 200 nanometers in diameter. Typical HIV particles are around 100–130 nanometers.

The article describes Gag’s role as helping build new particles; it does not give a detailed account of its molecular structure or every step of assembly. The abnormal particles can still fuse with and enter target cells, but they cannot establish productive infection. Understanding how lenacapavir acts on Gag as well as mature capsid may help guide improved capsid-targeting drugs and future HIV treatments.

05

What is the HIV capsid, and why is it an important target for antiviral drugs?

In general virology, the HIV capsid is a protein shell that encloses the virus’s genetic material and associated components. It is built from capsid proteins. The article refers to mature capsid protein and reports that lenacapavir also binds its precursor, Gag, which helps build new particles.

A capsid is an important antiviral target because its formation and function are essential parts of the viral life cycle. Drugs that interfere with capsid proteins can disrupt steps needed for HIV replication. In this study, binding to precursor Gag disturbed particle assembly, while the researchers also found binding to mature capsid protein.

The article presents lenacapavir as a powerful, long-acting drug used to prevent and treat HIV infection, and says it was already known to block key replication steps after entry into a cell. The newly described binding to Gag adds an effect during formation of new particles. Researchers hope such insights will guide improved capsid-targeting drugs and next-generation treatments.

06

What happens during the assembly and release stages of HIV’s life cycle?

Assembly and release are late stages in HIV’s life cycle. In general virology, viral components are brought together to form new particles inside an infected cell, and those particles then leave the cell. The article focuses on these stages because the researchers investigated how lenacapavir affects HIV-1 as new particles are assembled and released.

Gag helps build new particles. The team found that lenacapavir binds to this precursor protein, disrupting normal assembly and promoting unusually large virus-like particles. The study also reports binding to mature capsid protein. The resulting particles measure more than 200 nanometers across, compared with around 100–130 nanometers for typical HIV particles.

The abnormal particles can still fuse with and enter target cells, but they cannot establish productive infection. The study therefore identifies particle formation as another stage at which lenacapavir can interfere with HIV. The researchers hope this understanding will help guide improved capsid-targeting drugs and next-generation HIV treatments.

07

What must a virus do inside a host cell to make new infectious copies of itself?

In general, a virus must get into a host cell and use the cell to carry out the steps needed to make new virus particles. For those copies to spread infection, they must be produced and released in a form that can infect other cells. The article focuses on HIV’s replication and on the assembly and release of new particles.

The study gives a striking example of why cell entry alone is not enough. Lenacapavir disrupts particle assembly by binding to Gag, a precursor protein that helps build new HIV particles. The resulting abnormal particles can still fuse with and enter target cells, but they cannot establish productive infection.

The article does not detail every step HIV must complete inside a cell. It does report that lenacapavir is already known to block key replication steps after entry, and that the new findings show an effect during particle formation too. The researchers hope the added understanding will support improved capsid-targeting drugs and next-generation HIV treatments.

This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.

Read more in the JupiteX app

Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.

Or read more news on the web